(Bloomberg) Sosei Group Corp. has lost over half of its market value in just three days on concern about its outlook after Pfizer Inc. said Monday it will discontinue the partnered development of a diabetes and obesity drug.Most Read from BloombergSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkrainePutin Claims He’s Back in Control. Russia’s Elite Isn’t SureQatar Group Now Confident of Winning Manchester United RaceSweden Police Give Permit to Koran Burning Near Stockholm MosqueUBS Pr
A new Eli Lilly experimental drug has helped patients lose 24 percent of their weight, according to new mid-stage clinical trial results. The results, released on Monday, followed 338 adults, nearly 52 percent of whom were men, who were obese or overweight and had either received Eli Lilly’s retatrutide injection or a placebo treatment. Eli…
Compared to orforglipron, Novo Nordisk’s Ozempic and Wegovy recently approved for weight loss are given as once-weekly injections; and Lilly’s diabetes drug Mounjaro, which also helps substantial weight loss, is an injectable medicine.
Dice's lead drug DC-806, which is currently in a mid-stage trial, is an immunology drug for a skin condition called psoriasis and other diseases. The drug's mechanism is similar to Lilly's Taltz and works by inhibiting a protein called IL-17, which provides inflammatory signal. Indianapolis-headquartered Lilly is focusing on immunology to drive future growth, along with a widely expected approval of obesity drug candidate tirzepatide.